DN
Therapeutic Areas
Daiichi Sankyo Pipeline
| Drug | Indication | Phase |
|---|---|---|
| ENHERTU (fam-trastuzumab deruxtecan) | HER2+ Breast Cancer (post-neoadjuvant) | Phase 3 |
| ENHERTU | HER2+ Gynecologic Cancers | Phase 3 |
| DATROWAY (datopotamab deruxtecan) | TROP2+ Cancers | Approved |
| VANFLYTA (quizartinib) | Acute Myeloid Leukemia | Approved |
| TURALIO (pexidartinib) | Tenosynovial Giant Cell Tumor | Approved |
| INJECTAFER (ferric carboxymaltose) | Iron Deficiency | Approved |
Leadership Team at Daiichi Sankyo
KK
Ken Keller
Chairman, President & CEO of Daiichi Sankyo Inc. and Global Head of Oncology Business
KT
Ken Takeshita, MD
Global Head of Research & Development
DS
Daniel Switzer
Head of U.S. Oncology Business Division
RJ
Rich Jones
VP, Global Oncology Business Strategy & Analytics
AK
Ahmed Kotb, MD
Head of Global Oncology Medical Affairs
MG
Michael Grosso, MD, FACS
Global Head of Specialty Medicine Clinical Development
SM
Sandy Milligan, MD, JD
Head of Global Regulatory Affairs
MS
Michele Schmidt
Head of Asset Strategy & Project Management
DE
Dale E. Shuster, PhD
Head of Global Precision Medicine
BH
Brian Hauser
VP, US Sales